Skip to main content
Erschienen in: Familial Cancer 3/2017

09.02.2017 | Short Communication

A lesson from a reported pathogenic variant in Peutz-Jeghers syndrome: a case report

verfasst von: Hu Tan, Xianda Wei, Pu Yang, Yanru Huang, Haoxian Li, Desheng Liang, Lingqian Wu

Erschienen in: Familial Cancer | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Peutz-Jeghers syndrome (PJS) is a rare autosomal dominant disorder characterized by mucocutaneous hyperpigmentation, gastrointestinal (GI) hamartmatous polyps, and an increased risk of various malignancies. Pathogenic variants in the LKB1 tumor suppressor gene (also known as STK11) are the major cause of PJS. In this study, compound heterozygous variants of LKB1, c.890G > A/ c.1062C > G and del(exon1)/ c.1062C > G, were identified in two sporadic Chinese PJS cases respectively. Although all these three variants had been related to the autosomal dominant PJS in previous studies, all evidences collected in this study including de novo data, segregation data, population data, in-silico data, and functional data indicated that del(exon1) and c.890G > A are pathogenic in these two PJS families rather than c.1062C > G. This finding would contribute to genetic counseling for individuals carrying the variant c.1062C > G with or without PJS phenotypes. Moreover, this finding reminds genetic counselors that it is necessary to reevaluate the pathogenicity of reported variants in a known Mendelian disorder in order to avoid a misleading decision.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Giardiello FM, Trimbath JD (2006) Peutz-Jeghers syndrome and management recommendations. Clin Gastroenterol Hepatol 4(4):408–415CrossRefPubMed Giardiello FM, Trimbath JD (2006) Peutz-Jeghers syndrome and management recommendations. Clin Gastroenterol Hepatol 4(4):408–415CrossRefPubMed
2.
Zurück zum Zitat Jenne DE, Reimann H, Nezu J et al (1998) Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 18(1):38–43CrossRefPubMed Jenne DE, Reimann H, Nezu J et al (1998) Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 18(1):38–43CrossRefPubMed
3.
Zurück zum Zitat Volikos E, Robinson J, Aittomaki K et al (2006) LKB1 exonic and whole gene deletions are a common cause of Peutz-Jeghers syndrome. J Med Genet 43(5):e18CrossRefPubMedPubMedCentral Volikos E, Robinson J, Aittomaki K et al (2006) LKB1 exonic and whole gene deletions are a common cause of Peutz-Jeghers syndrome. J Med Genet 43(5):e18CrossRefPubMedPubMedCentral
4.
5.
Zurück zum Zitat Yajima H, Isomoto H, Nishioka H et al (2013) Novel serine/threonine kinase 11 gene mutations in Peutz-Jeghers syndrome patients and endoscopic management. World J Gastrointest Endosc 5(3):102–110CrossRefPubMedPubMedCentral Yajima H, Isomoto H, Nishioka H et al (2013) Novel serine/threonine kinase 11 gene mutations in Peutz-Jeghers syndrome patients and endoscopic management. World J Gastrointest Endosc 5(3):102–110CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Dai L, Fu L, Liu D et al (2014) Novel and recurrent mutations of STK11 gene in six Chinese cases with Peutz-Jeghers syndrome. Dig Dis Sci 59(8):1856–1861CrossRefPubMed Dai L, Fu L, Liu D et al (2014) Novel and recurrent mutations of STK11 gene in six Chinese cases with Peutz-Jeghers syndrome. Dig Dis Sci 59(8):1856–1861CrossRefPubMed
7.
Zurück zum Zitat Westerman AM, Entius MM, Boor PP et al (1999) Novel mutations in the LKB1/STK11 gene in Dutch Peutz-Jeghers families. Hum Mutat 13(6):476–481CrossRefPubMed Westerman AM, Entius MM, Boor PP et al (1999) Novel mutations in the LKB1/STK11 gene in Dutch Peutz-Jeghers families. Hum Mutat 13(6):476–481CrossRefPubMed
8.
Zurück zum Zitat Mehenni H, Gehrig C, Nezu J et al (1998) Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence for allelic and locus heterogeneity. Am J Hum Genet 63(6):1641–1650CrossRefPubMedPubMedCentral Mehenni H, Gehrig C, Nezu J et al (1998) Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence for allelic and locus heterogeneity. Am J Hum Genet 63(6):1641–1650CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Zeqiraj E, Filippi BM, Deak M, Alessi DR, van Aalten DM (2009) Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. Science 326(5960):1707–1711CrossRefPubMedPubMedCentral Zeqiraj E, Filippi BM, Deak M, Alessi DR, van Aalten DM (2009) Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. Science 326(5960):1707–1711CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Richards S, Aziz N, Bale S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405–424CrossRefPubMedPubMedCentral Richards S, Aziz N, Bale S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405–424CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Wang Z, Wu B, Mosig RA et al (2014) STK11 domain XI mutations: candidate genetic drivers leading to the development of dysplastic polyps in Peutz-Jeghers syndrome. Hum Mutat 35(7):851–858CrossRefPubMed Wang Z, Wu B, Mosig RA et al (2014) STK11 domain XI mutations: candidate genetic drivers leading to the development of dysplastic polyps in Peutz-Jeghers syndrome. Hum Mutat 35(7):851–858CrossRefPubMed
12.
Zurück zum Zitat Morton JP, Jamieson NB, Karim SA, et al (2010) LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology 139(2):586–97, 591–7CrossRefPubMedPubMedCentral Morton JP, Jamieson NB, Karim SA, et al (2010) LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology 139(2):586–97, 591–7CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Miyoshi H, Nakau M, Ishikawa TO, Seldin MF, Oshima M, Taketo MM (2002) Gastrointestinal hamartomatous polyposis in Lkb1 heterozygous knockout mice. Cancer Res 62(8):2261–2266PubMed Miyoshi H, Nakau M, Ishikawa TO, Seldin MF, Oshima M, Taketo MM (2002) Gastrointestinal hamartomatous polyposis in Lkb1 heterozygous knockout mice. Cancer Res 62(8):2261–2266PubMed
14.
Zurück zum Zitat Salloch H, Reinacher-Schick A, Schulmann K et al (2010) Truncating mutations in Peutz-Jeghers syndrome are associated with more polyps, surgical interventions and cancers. Int J Colorectal Dis 25(1):97–107CrossRefPubMed Salloch H, Reinacher-Schick A, Schulmann K et al (2010) Truncating mutations in Peutz-Jeghers syndrome are associated with more polyps, surgical interventions and cancers. Int J Colorectal Dis 25(1):97–107CrossRefPubMed
15.
Zurück zum Zitat Masuda K, Kobayashi Y, Kimura T, et al (2016) Characterization of the STK11 splicing variant as a normal splicing isomer in a patient with Peutz-Jeghers syndrome harboring genomic deletion of the STK11 gene. Hum Genome Var 3:16002CrossRefPubMedPubMedCentral Masuda K, Kobayashi Y, Kimura T, et al (2016) Characterization of the STK11 splicing variant as a normal splicing isomer in a patient with Peutz-Jeghers syndrome harboring genomic deletion of the STK11 gene. Hum Genome Var 3:16002CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Beggs AD, Latchford AR, Vasen HF et al (2010) Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut 59(7):975–986CrossRefPubMed Beggs AD, Latchford AR, Vasen HF et al (2010) Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut 59(7):975–986CrossRefPubMed
Metadaten
Titel
A lesson from a reported pathogenic variant in Peutz-Jeghers syndrome: a case report
verfasst von
Hu Tan
Xianda Wei
Pu Yang
Yanru Huang
Haoxian Li
Desheng Liang
Lingqian Wu
Publikationsdatum
09.02.2017
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 3/2017
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-016-9963-8

Weitere Artikel der Ausgabe 3/2017

Familial Cancer 3/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.